DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Short Interest Update

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) was the recipient of a significant increase in short interest in February. As of February 15th, there was short interest totalling 232,300 shares, an increase of 21.1% from the January 31st total of 191,900 shares. Based on an average trading volume of 113,800 shares, the days-to-cover ratio is currently 2.0 days.

Hedge Funds Weigh In On DiaMedica Therapeutics

A number of hedge funds have recently modified their holdings of DMAC. Point72 Asia Singapore Pte. Ltd. bought a new stake in DiaMedica Therapeutics in the third quarter valued at $40,000. Balyasny Asset Management L.P. bought a new stake in shares of DiaMedica Therapeutics in the 4th quarter worth about $79,000. Y Intercept Hong Kong Ltd acquired a new stake in shares of DiaMedica Therapeutics during the 4th quarter worth about $81,000. Raymond James Financial Inc. acquired a new stake in shares of DiaMedica Therapeutics during the 4th quarter worth about $83,000. Finally, Bank of Montreal Can bought a new position in DiaMedica Therapeutics during the 4th quarter valued at about $84,000. 10.12% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and issued a $7.00 price objective on shares of DiaMedica Therapeutics in a research note on Friday, November 15th.

DiaMedica Therapeutics Price Performance

Shares of DiaMedica Therapeutics stock opened at $5.95 on Friday. DiaMedica Therapeutics has a 52-week low of $2.14 and a 52-week high of $6.82. The firm has a market capitalization of $254.43 million, a PE ratio of -10.62 and a beta of 1.52. The company’s fifty day moving average price is $5.91 and its two-hundred day moving average price is $4.98.

DiaMedica Therapeutics Company Profile

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.